

FREE LEMS TEST TO START THEM ON THEIR WAY



CATALYST PHARMACEUTICALS
NO-COST ANTIBODY DIAGNOSTIC
TESTING PROGRAM

Complimentary anti-VGCC antibody testing from Catalyst may help facilitate earlier diagnosis of Lambert-Eaton myasthenic syndrome (LEMS)

Catalyst Pharmaceuticals, in collaboration with a national diagnostic lab provider, will offer free anti-voltage-gated calcium channel (VGCC) antibody tests for adults with symptoms suggestive of LEMS.

- The test is available to adult patients who already have a negative AChR antibody test or an equivocal EMG test for LEMS

Anti-VGCC antibody testing provides the differential diagnosis that can help move patients forward

Misdiagnosis is common with LEMS—studies suggest that more than half of adults with LEMS receive an initial misdiagnosis.^{1,2} Fortunately, testing for the presence of anti-VGCC antibodies can confirm diagnosis.



The presence of anti-VGCC antibodies can be detected in up to 90% of patients with LEMS.^{3,4}

For more information,
visit FreeLEMStest.com
or call 1-833-422-8259.

PERSONALIZED SUPPORT THROUGHOUT THEIR JOURNEY



**Complimentary one-on-one support
that covers patients and their families
from diagnosis through treatment**

Diagnosis is just the first step on the journey forward. Once LEMS has been confirmed, patients face new challenges, such as gaining access to affordable treatment or finding reliable sources of educational information.

Catalyst Pathways™ is designed to ease the burden of disease with a dedicated team of trained specialists and a broad array of programs and services that support adult patients and their families every step of the way.



Complimentary Starter Program

Helps eligible, new adult patients start strong with up to 60 days of treatment at no charge and includes titration support



Comprehensive Financial Assistance

Allows adult patients to access multiple options to help offset costs, including copay assistance to reduce out-of-pocket costs to \$0/month for commercially insured patients



Care Coordinator

Patients' first point of contact after enrollment who introduces them to their team, explains available resources, and manages prescription fulfillment



Patient Access Liaison

Your patients' dedicated, local resource with deep healthcare experience who provides one-on-one disease or treatment education and in-person support



Insurance Navigator

A representative who works directly with payers, prescribers, and their office staff to help resolve insurance and reimbursement issues that may arise

For more information, visit CatalystPathways.com.

References: 1. Merino-Ramírez MÁ, Bolton CF. Review of the diagnostic challenges of Lambert-Eaton syndrome revealed through three case reports. *Can J Neurol Sci.* 2016;43(5):635-647. 2. Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. *Lancet Neurol.* 2011;10(12):1098-1107. 3. Lennon VA, Kryzer TJ, Griesmann GE, et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. *N Engl J Med.* 1995;332(22):1467-1474. 4. Motomura M, Lang B, Johnston I, Palace J, Vincent A, Newsom-Davis J. Incidence of serum anti-P/Q-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. *J Neurol Sci.* 1997;147(1):35-42.



© 2021 Catalyst Pharmaceuticals, Inc. All Rights Reserved.
Printed in USA. 21CRP0247 June 2021